NR2 antibodies as diagnostic and prognostic stroke biomarker
https://doi.org/10.18705/1607-419X-2020-26-1-27-36
Abstract
Given the high percentage of disability and mortality resulting from a stroke, search of new ways to improve early diagnosis and optimize therapeutic approaches is highly relevant. The article reviews the studies of NR2 antibodies to glutamate N-methyl-D-aspartate (NMDA) receptors as a biomarker in acute stroke. The review shows that this biomarker is suitable for determining the presence of ischemic process in the brain and the degree of destruction of brain tissue, both in the first hours of stroke and at follow-up. In addition, the analysis of NR2 antibodies can be informative to predict the worsening, the increase in the locus size, which can contribute to the timely correction of treatment and will improve the effectiveness of the therapy. The prognostic potential of NR2 antibodies can be used for personalized therapeutic approach. However, currently the lack of studies of NR2 antibodies in acute stroke requires further study of this biomarker.
About the Authors
M. P. Topuzova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Mariya P. Topuzova, MD, PhD, Senior Researcher, Associate Professor, Department of Neurology and Psychiatry, Senior Researcher, Research Laboratory of Cerebrovascular Pathology, Research Department of Neurology and Neurorehabilitation
2 Akkuratov street, St Petersburg, 197341
T. M. Alekseeva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Tat’yana M. Alekseeva, MD, PhD, DSc, Associate Professor, Head, Department of Neurology and Psychiatry, Head, Research Laboratory of Cerebrovascular Pathology, Research Department of Neurology and Neurorehabilitation
St Petersburg
E. B. Panina
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Elena B. Panina, MD, PhD, Associate Professor, Department of Neurology and Psychiatry
St Petersburg
T. V. Vavilova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Tat’yana V. Vavilova, MD, PhD, DSc, Professor, Head, Department of Laboratory Medicine and Genetics
St Petersburg
M. L. Pospelova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Maria L. Pospelova, MD, PhD, DSc, Leading Researcher, Laboratory of Cerebrovascular Pathology, Research and Development Department of Neurology and Neurorehabilitation, Associate Professor, Department of Neurology and Psychiatry
St Petersburg
N. E. Ivanova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Natalia E. Ivanova, MD, PhD, DSc, Professor, Head, Scientific Department, Russian Neurosurgical Institute named after professor A. L. Polenova branch of Almazov National Medical Research Centre
St Petersburg
References
1. Feigin VL, Norrving B, George MG, Foltz JL, Roth GA, Mensah GA. Prevention of stroke: a strategic global imperative. Nat Rev Neurol. 2016;12(9):501–512. doi:10.1038/nrneurol.2016.107
2. Castellanos MI, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis. 2007;24(1):7–15. doi.org/10.1159/000107374
3. Strimbu K, Tavel JA. What are biomarkers? Current Opinion in HIV and AIDS. 2010;5(6):463–466. doi:10.1097/coh.0b013e32833ed177
4. Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. doi:10.1067/mcp.2001.113989
5. Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R. Biochemical markers in acute ischemic stroke. CMAJ. 2000; 162(8):1139–1140.
6. Kogure T, Kogure K. Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin Neurosci. 1997;4(4):179–183.
7. Shimada N, Graf R, Rosner G, Wakayama A, George CP, Heiss WD. Ischemic flow threshold for extracellular glutamate increase in cat cortex. J Cereb Blood Flow Metab. 1989;9(5): 603–606.
8. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981;54(6):773–782.
9. Coffey ET, Sihra TS, Nicholls DG, Pocock JM. Phosphorylation of synapsin I and MARCKS in nerve terminals is mediated by Ca 2+ entry via an Aga-GI sensitive Ca2+ channel which is coupled to glutamate exocytosis. FEBS Lett. 1994;353:264–268.
10. Mena FV, Baab PJ, Zielke CL, Zielke HR. In vivo glutamine hydrolysis in the formation of extracellular glutamate in the injured rat brain. J Neurosci Res. 2000;60(5):632–641.
11. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130(4S):1007S-1015S. doi:10.1093/jn/130.4.1007S
12. Platt SR. The role of glutamate in central nervous system health and disease — a review. Vet J. 2007;173(2):278–286. doi:10.1016/j.tvjl.2005.11.007
13. Okubo Y, Sekiya H, Namiki S, Sakamoto H, Iinuma S, Yamasaki M et al. Imaging extrasynaptic glutamate dynamics in the brain. Proc Natl Acad Sci USA. 2010;107(14):6526–6531. doi:10.1073/pnas.0913154107
14. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987;7(2):357–368.
15. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43(5):1369–1374.
16. Meldrum B, Evans M, Griffiths T, Simon R. Ischaemic brain damage: the role of excitatory activity and of calcium entry. Br J Anaesth. 1985;57(1):44–46.
17. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13:171–182.
18. Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010;15(11):1382–1402.
19. Hugon J, Vallat JM, Dumas M. Role of glutamate and excitotoxicity in neurologic diseases. Rev Neurol. 1996;152(4): 239–248.
20. Sharp CD, Fowler M, Jackson TH, Houghton J, Warren A, Nanda A et al. Human neuroepithelial cells express NMDA receptors. BMC Neurosci. 2003;4:28.
21. Karadottir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature. 2005;438(7071):1162–1166.
22. Del Valle-Pinero AY, Suckow SK, Zhou Q, Perez FM, Verne GN, Caudle RM. Expression of the N-methyl-D-aspartate receptor NR1 splice variants and NR2 subunit subtypes in the rat colon. Neuroscience. 2007;147(1):164–173.
23. Burns GA, Stephens KE, Benson JA. Expression of mRNA for the N-methyl-D-aspartate (NMDAR1) receptor by the enteric neurons of the rat. Neurosci Lett. 1994;170(1):87–90.
24. Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009;361(3):302–303. doi:10.1056/NEJMcibr0902052
25. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007;8(6):413–426.
26. Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna). 2014;121(8):1029–1075. doi:10.1007/s00702-014-1193-3
27. Rosenmund C, Stern-Bach Y, Stevens CF. The tetrameric structure of a glutamate receptor channel. Science. 1998;280 (5369):1596–1599.
28. Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. Nature. 2005; 438(7065):185–192.
29. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature. 1998;393(6683):377–381.
30. Gappoeva MU, Izykenova GA, Granstrem OK, Dambinova SA. Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc). 2003;68(6):696–702. In Russian.
31. Gascon S, Deogracias R, Sobrado M, Roda JM, Renart J, Rodríguez-Peña A et al. Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulation and cerebral ischemia. J Biol Chem. 2005;280(41):35018–35027.
32. Gingrich MB, Traynelis SF. Serine proteases and brain damage — is there a link? Trends Neurosci. 2000;23(9):399–407. https://doi.org/10.1016/s0166-2236(00)01617-9
33. Gascon S, Sobrado M, Roda JM, Rodríguez-Peña A, Díaz-Guerra M. Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol Psychiatry. 2008;13(1):99–114.
34. Dong YN, Waxman EA, Lynch DR. Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit control calpain-mediated cleavage of the NMDA receptor. J Neurosci. 2004;24(49):11035–11045.
35. Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002;33(5):1181–1182. doi:10.1161/01.str.0000014922.83673.86
36. Dambinova SA, Skoromets AA, Skoromets AP. Biomarkers of cerebral ischemia. Development, research and practical implementation. SPb.: OOO “IPK Kosta”, 2013. 336 p. In Russian.
37. Bokesch PM, Izykenova GA, Justice JB, Easley KA, Dambinova SA. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke. 2006;37(6):1432–1436.
38. Bidari A, Vaziri S, Moazen Zadeh E, Farahmand S, Talachian E. The value of serum NR2 antibody in prediction of post-cardiopulmonary resuscitation survival. Emerg (Tehran). 2015;3(3):89–94.
39. Huseynova S, Panakhova N, Orujova P, Hasanov S, Guliyev M, Orujov A. Elevated levels of serum sICAM-1 in asphyxiated low birth weight newborns. Sci Rep. 2014;4:6850. doi:10.1038/srep06850
40. Gusev EI, Skvortsova VI, Izykenova GA, Alekseev AA, Dambinova SA. The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S. S. Korsakova = Zh Nevrol Psikhiatr S S Korsakova. 1996;96(5):68–72. In Russian.
41. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49(10):1752–1762. doi:10.1373/49.10.1752
42. Dambinova SA, Bettermann K, Glynn T, Tews M, Olson D, Weissman JD et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One. 2012;7(7): e42362. doi:10.1371/journal.pone.0042362
43. Dambinova SA, Aliev KT, Bondarenko EV, Ponomarev GV, Skoromets AA, Skoromets AP, et al. The biomarkers of cerebral ischemia as a new method for the validation of the efficacy of cytoprotective therapy. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova = Zh Nevrol Psikhiatr S S Korsakova. 2017;117(5):62–67. doi:10.17116/jnevro20171175162–67. In Russian.
44. Stanca DM, Mărginean IC, Soriău O, Drago C, Mărginean M, Mureanu DF et al. GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases. J Cell Mol Med. 2015;19(9):2253–2261. doi:10.1111/jcmm.12614
45. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011;300(1–2):97–102. doi:10.1016/j.jns.2010.09.023
46. Klimenko LL, Skalny AV, Turna AA, Tinkov AA, Budanova MN, Baskakov IS et al. Serum trace element profiles, prolactin, and cortisol in transient ischemic attack patients. Biol Trace Elem Res. 2016;172(1):93–100. doi:10.1007/s12011-015-0586-y
47. Skalny AV, Klimenko LL, Turna AA, Budanova MN, Baskakov IS, Savostina MS et al. Serum trace elements are associated with hemostasis, lipid spectrum and inflammatory markers in men suffering from acute ischemic stroke. Metab Brain Dis. 2017;32(3):779–788. doi:10.1007/s11011-017-9967-6
48. González-García S, González-Quevedo A, Hernandez-Diaz Z, Alvarez Camino L, Peña-Sanchez M, Cordero-Eiriz A et al. Circulating autoantibodies against the NR2 peptide of the NMDA receptor are associated with subclinical brain damage in hypertensive patients with other pre-existing conditions for vascular risk. J Neurol Sci. 2017;375:324–330. doi:10.1016/j.jns.2017.02.028
Review
For citations:
Topuzova M.P., Alekseeva T.M., Panina E.B., Vavilova T.V., Pospelova M.L., Ivanova N.E. NR2 antibodies as diagnostic and prognostic stroke biomarker. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2020;26(1):27-36. (In Russ.) https://doi.org/10.18705/1607-419X-2020-26-1-27-36
Views:
1021
Email this article 